<DOC>
	<DOCNO>NCT00002350</DOCNO>
	<brief_summary>To evaluate safety immune response HIV-infected patient treat multiple injection APL 400-003 vaccine . PER 2/27/96 AMENDMENT : To evaluate safety vaccine administer via Biojector 2000 Needle-Free Injection Management System . Facilitated DNA inoculation , new type DNA vaccine , involve direct injection non-infectious HIV gene patient 's muscle , along agent promote uptake gene host cell . Host cell take gene produce viral protein form elicits immune response form antibody , killer T-cells , helper T-cells . The safety new vaccine approach need assess . PER 2/27/96 AMENDMENT : The Biojector 2000 provide option deliver vaccine without needle employ single-use syringe avoid cross-contamination .</brief_summary>
	<brief_title>A Phase I Trial APL 400-003 Vaccine : Safety Immune Response Evaluations Multiple Injections Escalating Doses Asymptomatic HIV-Infected Patients</brief_title>
	<detailed_description>Facilitated DNA inoculation , new type DNA vaccine , involve direct injection non-infectious HIV gene patient 's muscle , along agent promote uptake gene host cell . Host cell take gene produce viral protein form elicits immune response form antibody , killer T-cells , helper T-cells . The safety new vaccine approach need assess . PER 2/27/96 AMENDMENT : The Biojector 2000 provide option deliver vaccine without needle employ single-use syringe avoid cross-contamination . Patients give intramuscular injection APL 400-003 one three dos ( 30 , 100 , 300 mcg ) day 0 week 10 20 , follow 16 week final dose . An 8-week period prior initial dosing require immortalizing patient 's PBMCs . PER 2/27/96 AMENDMENT : Five patient evaluate 300 mcg dose Biojector 2000 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Low dos nonprescription NSAIDS , acetaminophen , ibuprofen , aspirin , replacement hormone therapy , vitamin supplement . Patients must : Asymptomatic HIV infection acute related infection . CD4 count &gt; = 500 cells/mm3 . Normal hematologic , renal , hepatic , metabolic , endocrine function . NOTE : No one patient 50 year age permit dose level . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Residual toxicity prior drug treatment . Hypersensitivity bupivacaine amidetype local anesthetic . Active viral hepatitis , autoimmune disorder , debilitate chronic disease . Concurrent Medication : Excluded : Medications affect immune function . Antiretrovirals . Patients follow prior condition exclude : Malignancies curatively treat basal cell squamous cell carcinoma skin carcinoma situ cervix . History anaphylaxis vaccine . Prior Medication : Excluded : Prior immunization experimental HIV vaccine . Other experimental therapy within 30 day prior study entry . Prior cancer chemotherapy . Antiretrovirals within 3 month prior study entry . Prior Treatment : Excluded : Prior radiotherapy . IV drug use highrisk behavior .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 1997</verification_date>
	<keyword>Vaccines , Synthetic</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>DNA , Viral</keyword>
</DOC>